A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: 1. Subjects who are ≥ 18 years of age 2. Participant has a histologically or cytologically confirmed diagnosis of MM as defined by IMWG criteria 3. Participant has Eastern Cooperative Oncology Group (ECOG) performance status of score of 0, 1, or 2 4. Participant is considered transplant ineligible or for participants with a history of autologous stem cell transplant (ASCT), ASCT was \>100 days before initiating study treatment 5. Participant has measurable disease with at least one of the following criteria: * Serum M protein \>0.5 g/dL (\>5 g/L), or * Urine M protein \>200 mg/24h, or * Serum free light chain (FLC) assay: Involved FLC level \>5 mg/dL (\>50 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65) 6. Participant is quadruple-class exposed or refractory (anti-CD38 antibody (e.g., daratumumab, isatuximab) alone or in combination, immunomodulatory agent (e.g., lenalidomide, pomalidomide), a proteasome inhibitor (e.g., bortezomib, ixazomib, car…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source